Suscribirse

Cardiovascular consequences of parathyroid disorders in adults - 25/05/21

Conséquences cardiovasculaires des troubles parathyroïdiens chez l’adulte

Doi : 10.1016/j.ando.2020.02.003 
Jens Bollerslev a, b, , Evelina Sjöstedt c, d, Lars Rejnmark e, f
a Section of Specialized Endocrinology, Division of Medicine, Oslo University Hospital, University in Oslo, Oslo, Norway 
b Faculty of Medicine, University in Oslo, Oslo, Norway 
c Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden 
d Department of Neuroscience, Karolinska Institute, Stockholm, Sweden 
e Department of Clinical Medicine, Aarhus University, Aarhus University Hospital, Aarhus, Denmark 
f Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark 

*Corresponding author at: Faculty of Medicine, University in Oslo, Oslo, Norway.Faculty of Medicine, University in OsloOsloNorway

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

PTH is a metabolic active hormone primarily regulating calcium and phosphate homeostasis in a very tight and short term-manner. Parathyroid disorders in adult patients reflect a variety of different conditions related either to the parathyroid glands itself or to the effects of the secreted hormone. The clinical spectrum varies from the common disease primary hyperparathyroidism (PHPT) to the orphan conditions pseudohypoparathyroidism (Ps-HypoPT) and chronic hypoparathyroidism (HypoPT). The purpose of this review is to describe the consequences of disturbances in levels or action of PTH for cardiac function and cardiovascular risk in adult patients with these disorders. Most patients with PHPT achieve the diagnose by chance and have minor or no specific symptoms. Still, these patients with mild PHPT do possess cardiovascular (CV) morbidity, however so far not proven ameliorated by surgery in controlled trials. In severe cases, the CV risk is increased and with a potential reversibility by treatment. Patients with Ps-HypoPT have resistance to PTH action, but not necessarily total resistance in all tissues. So far, no clear CV morbidity or risk has been demonstrated, but there are several aspects of interest for further studies. Most patients with HypoPT do get their hormonal deficiency syndrome following neck surgery. These patients do experience multiple symptoms and do have an increased CV-risk before the primary surgery. Based on existing data, their CV mortality do not deviate from the expected when adjusting for the preexisting increased risk. Patients with nonsurgical (NS-) HypoPT do demonstrate increased CV-risk also associated with exposure time. Endocrine disorders with alterations in PTH function have major impact on the cardiovascular system of importance for morbidity and mortality, wherefore management of these specific diseases should be optimized currently, as new data become available, however also avoiding over-treating asymptomatic patients.

El texto completo de este artículo está disponible en PDF.

Keywords : Heart, Cardiovascular, PTH, Calcium, Hyperparathyroidism, Hypoparathyroidism, Pseudohypoparathyroidism


Esquema


© 2020  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 82 - N° 3-4

P. 151-157 - juin 2021 Regresar al número
Artículo precedente Artículo precedente
  • PTH and cardiovascular risk
  • Damien Gruson
| Artículo siguiente Artículo siguiente
  • Thyroid hormone and mammalian tissue regeneration
  • Frédéric Flamant

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.